We generated a replicating chimeric measles virus in which the hemagglutinin and fusion surface glycoproteins were replaced with the gp160 envelope glycoprotein of simian immunodeficiency virus (SIVmac239). Based on a previously cloned live-attenuated Schwarz vaccine strain of measles virus (MV), this chimera was rescued at high titers using reverse genetics in CD4+ target cells. Cytopathic effect consisted in the presence of large cell aggregates evolving to form syncytia, as observed during SIV infection. The morphology of the chimeric virus was identical to that of the parent MV particles. The presence of SIV gp160 as the only envelope protein on chimeric particles surface altered the cell tropism of the new virus from CD46+ to CD4+ cells. Used as an HIV candidate vaccine, this MV/SIVenv chimeric virus would mimic transient HIV-like infection, benefiting both from HIV-like tropism and the capacity of MV to replicate in dendritic cells, macrophages and lymphocytes.
Introduction
Almost thirty years after human immunodeficiency virus (HIV) was identified as the causative agent of AIDS, a vaccine capable of preventing the infection remains elusive. In 2003, the first phase III efficacy trial of an HIV candidate vaccine demonstrated that a monomeric recombinant gp120 (AIDSVax) was unable to elicit detectable neutralizing antibodies or to reduce viral load (Flynn et al., 2005; Pitisuttithum et al., 2006) . In 2008, the STEP phase IIb trial of an Ad5-based vaccine challenged the rationale underlying T-cellbased vaccine strategies, as specific T cell responses induced by the vaccine also failed to prevent HIV infection or to reduce viral load McElrath et al., 2008) . Recently, the RV144 phase III trial conducted in Thailand showed that a prime-boost strategy combining 6 doses of live-recombinant ALVAC-HIV with 2 doses of gp120 B/E envelope in at-risk healthy volunteers reduced the incidence of infection by 31% (Rerks-Ngarm et al., 2009) . This very encouraging result demonstrated that both T cells and antibodies are required to prevent HIV infection, and that a prime-boost strategy is necessary to induce both arms of the immune system. However, the complex dosing schedule and weak protection provided by this strategy makes it impractical.
An ideal vaccine would induce effective and long-lasting responses after one or two administrations and be amenable to low-cost mass production. To address these challenges, we have previously developed a vector derived from the pediatric live-attenuated Schwarz vaccine strain of measles virus (MV) (Combredet et al., 2003) . Different HIV and SIV proteins were stably expressed from MV vectors and strong and durable specific humoral and cellular immune responses were induced in mice (Guerbois et al., 2009; Liniger et al., 2009; Lorin et al., 2004 Lorin et al., , 2005a Wang et al., 2001) . MV vaccine is a live-attenuated negative-stranded RNA virus proven to be one of the safest and most effective human vaccine products. Mass-produced in many countries and distributed at low cost through the Extended Program on Immunization, the MV vaccine induces life-long immunity after one or two injections. We subsequently initiated clinical development of an HIV candidate vaccine based on a recombinant MV encoding an HIV Gag-Pol-Nef antigen. This first-generation MV-HIV vector was designed to induce cellular immunity in adults with preexisting immunity to measles, to evaluate for the first time a replicating vector as an HIV vaccine, and to prepare the GMP and regulatory logistics for such a vaccine. A phase I clinical trial of this candidate vaccine was recently launched.
Measles vaccine provides very effective protection from an infection acquired through the respiratory mucosa. The effectors are both long-lived B cells that produce neutralizing antibodies to the viral glycoproteins, and long-lived CD4 and CD8 T cells. These effectors are rapidly mobilized in the respiratory mucosa on natural Virology 419 (2011) 117-125 exposure to the virus. Recent progress achieved on the natural course of MV infection in the macaque model has shown that the first cells infected are mucosal dendritic cells (de Swart, 2008; Lemon et al., 2011) . Mucosal tissues are also the main portals of entry for HIV-1. After transmission, HIV-1 crosses the mucosal barrier in a few hours and disseminates locally to draining lymph nodes after a few days (Pope and Haase, 2003) . Systemic dissemination then occurs, with a high rate of virus replication in blood cells during the following month. Thus, to induce sterilizing immunity to HIV-1, a vaccine must induce both neutralizing antibodies and cytolytic T lymphocytes (CTLs) at mucosal surfaces (Letvin, 2006) . These effectors must either be present at the time of natural exposure or be raised within a few hours or days.
Here, to exploit the ability of the live-attenuated MV to induce potent mucosal immunity to its surface glycoproteins, we developed a new approach based on an MV-HIV chimera rather than a recombinant MV vector. The chimeric virus was obtained by replacing the MV fusion (F) and hemagglutinin (H) glycoprotein genes by the HIV gp160 coding sequence expressed as an MV transcript in a recombinant MV vector. The resulting virus expresses native HIV gp160 spikes on its surface, instead of MV H/F glycoproteins. It should therefore have the twin advantages of HIV tropism and MV replication in dendritic cells, macrophages and lymphocytes, thus mimicking transient HIV infection. It should also exhibit the genetic stability and safety features of MV vaccine strains that include no recombination with other segmented negative-stranded RNA viruses, a cytoplasmic replicative cycle, no host genome integration, no persistence, and no shedding. Moreover, this chimera should be cleared from the host by the immune reaction it induces.
With the aim of evaluating its vaccine efficacy in the macaque model, we first generated a MV-SIV chimera based on SIVmac239, one of the most widely used model for AIDS in macaques. We constructed the chimera by deleting the fusion (F) and hemagglutinin (H) glycoprotein genes from MV Schwarz vaccine strain antigenomic cDNA and replacing them by the SIVMac239 gp160 sequence as an MV transcript. The chimeric virus was rescued with a reverse genetics system and produced at high titers in CEMx174 cells. SIV gp160 was efficiently expressed on the surface of infected cells and on viral particles. The new virus exhibited typical CD4 tropism and induced syncytia formation by CD4 T cells.
Results

Generation of chimeric MV expressing SIVMac239 gp160 instead of the MV H/F envelope glycoproteins
To improve the capacity of our previous pTM-MVSchw vector to elicit broad-spectrum neutralizing antibodies to HIV by expressing native trimeric gp160 on the viral surface, we designed a new MV chimeric vector in which the MV fusion (F) and hemagglutinin (H) envelope glycoproteins genes were deleted and replaced by the gp160 sequence expressed from an MV transcript. As proof-of-concept, and with the aim of evaluating vaccine efficacy in the macaque model, we generated an MV-SIV chimeric virus based on SIVmac239 gp160 (Fig. 1) . To promote efficient expression of SIV gp160 glycoprotein at the surface of chimeric viral particles, we replaced the intracytoplasmic domain of gp160 with that of the MV fusion protein, thus permitting cell membrane anchoring through interactions with the MV matrix protein, as previously demonstrated (Foley et al., 2002; Spielhofer et al., 1998) . To visualize the chimeric virus in infected cells, we inserted the RFP Cherry protein sequence as an additional transcription unit, upstream of the MV-M matrix protein. This additional transcription unit may be used in future to insert other genes in place of RFP.
To construct the chimeric cDNA, the genomic region encompassing the MV fusion (F) and hemagglutinin (H) genes (NarI to SpeI fragment in Fig. 1A ) was deleted from the vector plasmid pTM-MV-Schw and replaced by a synthetic chimeric MV-SIV sequence (Fig. 1B) . This chimeric sequence (Fig. 1C ) was designed to preserve the complete promoter and intergenic sequence of the MV-F gene upstream of the SIV gp160 initiation codon, such that the gp160 gene is expressed as an MV transcript. The whole gp120 and the gp41 ectodomain with its transmembrane sequence deleted of the intracytoplasmic domain were fused to the MV-F intracytoplasmic sequence, followed by the MV H/L intergenic region. This synthetic sequence was then introduced into the pTM-MVSchw-RFP-STREPtag plasmid, and the resulting vector, designated pTM-MVSchw-Chim-SIVenv (Cherry), was fully sequenced and shown to respect the 'rule of 6' of the MV genome (Calain and Roux, 1993) .
MV rescue from cDNA is usually achieved by coculturing transfected helper cells with MV target cells that express at least one of the MV receptors (SLAM or CD46) (Vero, MRC5, CEF, B95a) (Dorig et al., 1993; Naniche et al., 1993; Tatsuo et al., 2000) . Given the expected tropism change of the MV/SIV chimeric virus, we rescued it from the pTM-MVSchw-Chim-SIVenv (Cherry) plasmid by using the standard protocol, except that helper cells were cocultured with SIV CD4+ target cells (MT4, CEMx174). Rescue of the chimeric virus was only successful when this modified protocol was used. Monitoring was facilitated by the presence of fluorescent cells after 3 to 5 days of co-culture ( Fig. 2A) . A cytopathic effect (CPE) on CEMx174 cells appeared soon after fluorescence was first detected. The new chimeric virus harvested from infected cells was designated MV/SIVenv. Other cells, such as MT4 and HeLa P4C5 cells, were also successfully used to rescue the MV/SIVenv chimeric virus, with a comparable time course.
Once rescued, the chimeric virus can be amplified for weeks on CEMx174 or MT4 cells, simply by adding fresh uninfected cells to the culture and replacing the medium, as for lentivirus amplification. Using the same procedure as for measles virus purification, cell-free virus was collected by freezing and thawing infected cells with medium then clarification. New infection of other cells was carried out with clarified cell-free virus. T cells infected by the MV/ SIVenv chimeric virus exhibited characteristic features of lentiviral infection with large aggregates of infected cells evolving to form syncytia (Fig. 2B ). Although the MVSchw strain is able to grow at low titers on CD4 T cells through the use of the SLAM receptor (Dhiman et al., 2004; Yanagi et al., 2006) , the chimeric MV/SIVenv virus produced 3 log higher titers than control MVSchw on CEMx174 cells (Fig. 3A) . When comparing the rate of replication of SIV to the MV/SIVenv chimeric virus by FACS analysis (Fig. 3B) , we observed that the chimeric virus replicated faster with the maximum virus yield achieved at 2-3 days post-infection, while as expected, SIVmac251 replicated more slowly and required 8-10 days to achieve 100% of infection. Replication kinetic analysis showed that the MV/SIVenv chimeric virus achieved titers of up to 10 6 TCID 50 /ml within 48-60 h ( Fig. 3C ), at a similar rate than MV itself on Vero cells (Fig. 3D ). Beyond 60 h the virus titer fell and most of the cells die after few days. If additional fresh cells are added, the infection can last several weeks. To determine the best cell line for virus stock production and titration, we compared the viral titers obtained with CEMx174 and MT4 cells. CEMx174 cells reproducibly produced 1 log higher virus titers than MT4 cells. CEMx174 cells are B-T hybrid lymphoblastic cells (Salter et al., 1985) , a characteristic that might promote MV/SIVenv chimeric virus replication. The virus might also benefit from both the T cell entry receptor used by SIVenv glycoproteins and from the efficient replication of MV in B lymphocytes (Kobune et al., 1990) .
The MV/SIVenv chimeric virus expresses SIV gp160
To assess the expression of SIV gp160 glycoprotein by the chimeric virus, CEMx174 cells were infected with MV/SIVenv and lysed after 48 h. Cell extracts were separated by SDS-PAGE electrophoresis and analyzed by Western blotting (Fig. 4) 
The morphology of MV/SIVenv chimeric particles is similar to that of MV particles
To determine whether MV-F and H glycoprotein replacement by SIV gp160 alters the morphological structure of chimeric particles compared to parental MV, we examined infected cells by transmission electron microscopy. Hela P4C5 cells were infected with MV-Schw or MV/SIVenv, then fixed and stained with uranyl acetate and Reynolds lead citrate 22 h later, before electron microscopy (Fig. 6) . In both cases we observed numerous viral particles either budding or trapped in the extracytoplasmic space between infected cells, with a structure and size (150-350 nm) typical of measles virus. Moreover, a fringe of short spikes was observed on the surface of both MV and chimeric particles (Figs. 6C and D) , corresponding to the MV and SIV glycoproteins, respectively. These observations showed that MV F and H replacement by SIV gp160 did not affect the morphology or size of the resulting viral particles.
Immunoelectron microscopy was used to demonstrate the presence of SIV gp160 anchored on the surface of the virus membrane. Infected cells were immunostained with a specific anti-SIV gp160/120 antibody before electron microscopy (Fig. 6E) . The chimeric viral particles were surrounded by 10-nm gold particles, demonstrating the anchoring of SIV gp160 to their surface. Gold particles were also observed on the surface of budding viruses. In contrast, no gold particles were observed on the surface of MVSchw particles in control cells. We have previously observed that HIV gp160 expressed from recombinant MV, as an additional gene, is not incorporated on MV particles (Guerbois et al., 2009 ). The present observation validates our choice to anchor SIVgp160 with the intracytoplasmic tail of MV-F protein, as supported by previous studies (Foley et al., 2002; Rouxel et al., 2009; Spielhofer et al., 1998) .
The MV-SIVenv chimeric virus acquired HIV/SIV tropism
The aim of constructing a chimeric replicating MV expressing native SIV gp160 spikes on its surface was to obtain a virus targeting CD4+/CCR5+ cells, in the same way as HIV/SIV. Used as an HIV candidate vaccine, this virus would exhibit both HIV tropism and replicate in dendritic cells, macrophages and lymphocytes, thus mimicking transient HIV-like infection. To analyze the effect of the exchange of surface glycoproteins on viral tropism, we cultured the MV/SIVenv virus in different cell lines supporting the replication of HIV/SIV or MV. Attenuated MV vaccine strains are known to replicate inefficiently in CD4 T cells, which are the main targets of HIV and SIV. We thus compared the capacity of the MV/SIVenv chimeric virus to infect CD4+ cells, and fibroblastic cell lines that do not express CD4 receptors. Cells were infected at an MOI of 0.1, and infection was detected by the presence of CPE and red fluorescence. The MV/SIVenv chimeric virus replicated in all the CD4+/CCR5+ cells tested, namely CEMx174, MT4, HeLa P4C5, primary CD4+ human lymphocytes, and primary macaque splenocytes (Table 1) . Jurkat cells, which express only CXCR4 co-receptor, were poorly infected, confirming the tropism of SIVmac239 for CCR5. In contrast, CD4-negative cell lines such as Vero, MRC5, HeLa and U937 were unable to support MV/SIVenv infection. To confirm that the chimeric virus has lost its original CD46 tropism, we infected HeLa and Vero cells, which are typical CD46+ target cells for MV vaccine strains, with the parental MVSchw (Cherry) and MV/SIVenv (Cherry). We observed typical large syncytia with red fluorescence in HeLa and Vero cells infected by MVSchw, while no signs of infection were detected in the same cells infected with MV/SIVenv chimeric virus (Fig. 7) . In contrast, HeLa P4C5 cells were infected with the chimera (Fig. 7) . Overall, these results demonstrate that this chimeric MV has acquired the capacity to infect CD4+/CCR5+ cells, as SIV/HIV, and has lost his original tropism for non-CD4+ fibroblastic cells.
Discussion
We describe in this report the design, production and characterization of a replicating MV/SIV chimeric virus constructed by replacing the MV H and F surface glycoproteins with the SIV gp160 envelope glycoprotein. This chimeric virus was generated from a previously cloned live-attenuated Schwarz vaccine strain of measles virus (Combredet et al., 2003) . The SIV gp160 sequence was cloned downstream of the MV-F gene promoter and was followed by the MV H/L intergenic region, such that it is expressed as an MV transcript. The transmembrane domain of SIV gp41 was preserved in order to promote trimeric gp160 assembly, and the gp41 intracytoplasmic domain was replaced by the MV-F intracytoplasmic sequence in order to favor anchoring of the chimeric gp160 on MV particles. The presence of an additional transcription unit within the chimeric virus genome allows the expression of additional genes. We readily rescued the chimeric virus by coculturing transfected helper cells with CD4+ target cells. In infected CEMx174 cells, a cytopathic effect is reflected by the presence of large cell aggregates evolving to form syncytia, as observed during SIV infection. High viral titers were obtained after 2-3 days of culture. The chimeric virus replicated at the same rate than MV, which is much faster than SIV. This capacity might be an advantage for its immunogenic properties in vivo. The morphology of the chimeric virus was identical to that of the parent MV particles, indicating that MV particle morphology is not shaped by envelope proteins but rather by the matrix M protein (Spielhofer et al., 1998) . We detected SIV gp160 expression by the chimeric virus in cell lysates and on the surface of infected cells. The presence of gp160 anchored on the surface of viral particles was observed by immunoelectron microscopy. As expected from previous studies (Foley et al., 2002; Rouxel et al., 2009; Spielhofer et al., 1998) , successful incorporation of a foreign envelope protein on the surface of measles virus, as on rabies virus, depends strictly on the presence of the original intracytoplasmic domain interacting efficiently with the matrix M protein. When expressed with its own gp41 intracytoplasmic domain, HIV-1 gp160 was not incorporated on MV particles (Guerbois et al., 2009) . Specific sequences of HIV/SIV Env cytoplasmic tail have been shown to be responsible for slowing and reducing its cell and viral surface expression (Abrahamyan et al., 2005; Bultmann et al., 2001) . Replacing the cytoplasmic tail by that of MV-F protein likely abolished this property. Therefore, Env incorporation into virions might be enhanced. However, enumerating the number of Env trimers on the surface of virions is difficult and requires the use of complex techniques such as cryo-electron microscopy and specific antibodies of very high affinity that are poorly available for SIV. The antibodies that we used in this work did not allow enumerating accurately the number of Env trimers on the surface of chimeric virus. However, whatever the number of biologically active Env trimers on its surface, the infectivity of the chimeric virus was improved as compared to SIV because its replicative rate was accelerated as shown in Fig. 3C .
The presence of SIV gp160 as the only envelope protein on the surface of MV/SIVenv chimeric particles altered the cell tropism of the new virus from CD46+ epithelial cells to CD4+/CCR5+ cells (both cell lines and primary human and macaque cells). In contrast, CD4-negative cell lines such as Vero, MRC5 and U937, currently used to replicate MV, did not support MV/SIVenv infection, confirming that the chimeric virus had lost its original CD46 tropism. MV/SIVenv chimeric particles incorporate gp160 on their surface, and their budding progeny exhibit efficient fusion on CD4+/CCR5+ cells, indirectly demonstrating the functional trimeric configuration of gp160 that is required to elicit neutralizing antibodies (Mascola and Montefiori, 2010) . This efficient fusion capacity of chimeric gp160 is due to the capacity of the SIV gp41 transmembrane domain and the MV-F intracytoplasmic domain to assemble the envelope protein in trimeric form.
Used as an HIV candidate vaccine, the MV/SIVenv chimeric virus would mimic transient HIV-like infection, benefiting both from HIVlike tropism and the capacity of MV to replicate in dendritic cells, macrophages and lymphocytes. This might be expected to confer a level of protection similar to that provided by immunization with liveattenuated SIV, an approach that cannot be transposed to humans. HIV-1 mainly enters the body through mucosal sites during sexual intercourse. Thus, the presence of neutralizing antibodies and efficient cell-mediated immunity at these sites is crucial for preventing viral entry and early steps of dissemination (Montefiori and Mascola, 2009 ). Indeed, so-called elite HIV-1 controllers, who have persistently low viral load in the absence of therapy, have significantly stronger and more complex mucosal immune responses than antiretroviraltreated patients (Ferre et al., 2009) . It was recently reported that mucosal antibodies induced by efficient immunization fully protect primates from vaginal challenge (Bomsel et al., 2011) .
In the Call for replicating vector prime-protein boost strategies in HIV vaccine design (Malkevitch and Robert-Guroff, 2004) , it was elegantly demonstrated that replicating vectors expressing an optimally designed envelope have numerous advantages for the induction of protective mucosal immunity. The capacity of live-attenuated MV vaccines to induce strong and durable protective immunity mediated by CD4/CD8 T cells and persistent neutralizing antibodies to the viral envelope is probably related to a very specific gene signature, as demonstrated for the yellow fever vaccine YF-17D (Pulendran, 2009; Querec et al., 2009 ). Because such signatures result from the stress induced by the replicating vaccine virus, our MV/SIVenv chimera might benefit, as a candidate vaccine, from the capacity of MV to induce very potent mucosal protection mediated by neutralizing antibodies to surface glycoproteins. Administered to subjects with pre-existing immunity to MV, this chimeric virus would escape MV- neutralizing antibodies. It could also be used as a booster following administration of a recombinant MV. Live, non-persistent chimeric viruses based on the safest human live attenuated vaccine have not previously been evaluated as HIV candidate vaccines, although similar chimeric viruses are already developed for immunization against dengue and other arboviruses. Based on intertypic envelope exchange within the yellow-fever 17D vaccine backbone, this Chimerivax® technology shows promising clinical results (Guirakhoo et al., 2004; Guy et al., 2010) . There are currently no suitable mouse models in which to evaluate the immunogenicity and preventive efficacy of the MV/SIVenv candidate vaccine. Genetically modified CD46-IFNAR mice that express CD46 (the human receptor for MV vaccine strains) and lack the INF-α/β receptor are susceptible to MV infection (Mrkic et al., 1998 (Mrkic et al., , 1999 and have been used as a model to evaluate the immunogenicity of MV recombinants (Combredet et al., 2003; Desprès et al., 2005; Guerbois et al., 2009; Lorin et al., 2004 Lorin et al., , 2005b Singh et al., 1999) . However, these mice could not sustain the replication of our MV/SIVenv chimeric virus, which has lost its original tropism. Mice expressing SLAM, the human receptor for wild-type MV strains (Sellin et al., 2006; Welstead et al., 2005) , are also unsuitable. We will therefore evaluate the protective capacity of MV/SIVenv in the macaque model. With its Cherry protein marker, this virus will enable the cell types supporting gp160-dependent infection to be identified in vivo after intravenous or mucosal administration. The humoral and cell-mediated immunity elicited will be evaluated, and the capacity of different vaccination schedules to protect from autologous SIV MAC251 challenge will be assessed.
Materials and methods
Cells and tropism assay
Stable HEK-293-T7-NP human embryonic kidney cells generated by transduction with recombinant lentiviral vectors and cloning (Tangy et al., 2006) were used for viral rescue. They were maintained in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal calf serum. CEMx174 hybrid lymphoblastic cells were maintained in RPMI medium supplemented with 10% fetal calf serum (Salter et al., 1985) . P4C5 cells (HeLa, CD4+, CXCR4+, CCR5+, HIVLTR-LacZ+) (Marechal et al., 1998) were cultured in DMEM 10% FCS supplemented with 0.5 mg/ml G418 (Geniticin; Gibco). For tropism assays, primary human CD4+ T lymphocytes, primary Maccaca cynomolgus splenocytes, and the MT4, Jurkat, and U937 human cell lines were cultured in RPMI supplemented with 10% fetal calf serum. MRC5 and Vero cells were maintained in DMEM-Glutamax (Gibco-BRL) supplemented with 10% fetal calf serum.
Plasmid construction
The chimeric plasmid was constructed from the pTM-MVSchweGFP plasmid (Fig. 1A) , which contains an infectious MV cDNA corresponding to the antigenome of the Schwarz MV vaccine strain and expresses the eGFP protein in an additional transcription unit (Combredet et al., 2003) . The eGFP sequence was replaced by the sequence coding for RFP-STREPtag protein (Cherry red fluorescent protein) between the BsiW1 and BssHII sites. This tag protein was chosen because it is smaller and more sensitive than eGFP. To replace the MV envelope glycoprotein genes by those of SIV, the fragment between the two SpeI sites flanking the F and H genes in pTM-MVSchw-eGFP was removed and subcloned into a pBS vector, designated pBS-Schw-Spe5803. A chimeric cDNA was then synthesized (Genecust), containing successively, from NarI to SpeI: (i) the MV M/F intergenic region, (ii) the SIVmac239 gp160 sequence, in which the intracytoplasmic domain was replaced by that of MV-F, and (iii) the MV H/L intergenic region (Fig. 1C) . The SIVgp160 sequence was optimized to Macacca codon usage and modified to remove a SpeI restriction site and to avoid the following cis-active elements: internal TATA-boxes, chi-sites, ribosomal entry sites, AT-or GC-rich sequences, ARE, INS and CRS sequence elements, repeated sequences, RNA secondary structures, cryptic splice donor and acceptor sites, and branch points. This optimization also avoided MV editing-like sequences. The whole construct respected the 'rule of 6' of the MV genome (Calain and Roux, 1993) . A BamHI site was added to the 3′ end of the synthetic sequence to enable introduction of the cassette into the pBS-Schw-Spe5803 plasmid. To replace the MV H and F sequences by the modified SIVenv gene, the chimeric synthetic sequence was recombined into the pBS-Schw-Spe5803 plasmid after NarI/BamHI digestion. This plasmid was designated pBS-Schw-chim/siv/env. The new modified sequence was then introduced into the pTMMVSchw-RFP-STREPtag vector after SpeI digestion. The resulting vector was designated pTM-MVSchw-Chim-SIVenv (Cherry).
Rescue of the MV/SIV chimera
The chimeric MV/SIV virus was rescued from the pTM-MVSchwChim-SIVenv (Cherry) plasmid as previously described (Combredet et al., 2003) , by using a helper-cell-based rescue system (Radecke et al., 1995) (Parks et al., 1999) , modified to recover the virus in CD4 cells. Briefly, HEK-293-T7-MV human embryonic kidney helper cells (Guerbois et al., 2009; Tangy et al., 2006) were transfected with the pTM-MVSchw-Chim-SIVenv (Cherry) plasmid and then co-cultured with CEMx174 cells for 3 days. Positive rescue was shown by a cytopathic effect (CPE) and red fluorescence generated by the Cherry protein. CPE and red fluorescence generally appeared after 3-5 days of co-culture. To amplify the virus, fresh CEMx174 cells were added twice a week and culture was continued until almost all the cells were infected. To harvest the virus, cells were centrifuged and freezethawed. After clarification, cell lysates were titrated and used as an inoculum for subsequent virus production.
Virus titration and growth kinetics
Titers of the chimeric virus were determined by using an endpoint dilution assay on CEMx174 cells. Briefly, CEMx174 cells were infected for 2 h under low-speed centrifugation (1000 rpm) in sterile Eppendorff tubes with serial 1:10 dilutions of virus suspension in RPMI supplemented with 10% FCS. Infected cells were seeded in 96-well plates (25 000 cells in 100 μL of RPMI/well) and incubated for 24 h at 37°C. After 24 h, 100 μL of RPMI-10% FCS was added to each well and the cells were incubated for 4 days. The cells were observed daily for CPE and red fluorescence. Fiftypercent tissue culture infective doses (TCID50) were calculated with the Spearman and Kärber method. To determine the replicative capacity of the chimeric virus, CEMx174 cells were infected with viral suspension for 2 h at a multiplicity of infection (MOI) of 0.1, under low-speed centrifugation (1000 rpm). Infected CEMx174 cells were seeded in 12-well plates at 400 000 cells/well. At various times post-infection, cells were harvested and centrifuged at 1000 rpm. After a round of freeze thawing and removal of cell debris by low-speed centrifugation, virus titers were determined by limiting dilution assay on CEMx174 cells as described above. To compare the growth capacity of SIV to the chimeric virus, six-well plates were seeded with 10 6 CEMx174 cells and infected at a MOI 0. 
Immunofluorescence detection
To detect the expression of MV-N and SIV-env proteins, immunofluorescence staining was performed on infected HeLa P4C5 cells fixed with 4% PFA solution (v/v). Surface SIV-env immunostaining was performed after incubating the cells for 1 h in blocking solution (PBS 2% goat serum), with a 1/300-diluted mouse anti-SIVMac251gp160/gp120 monoclonal antibody (KK17; obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, from Dr Karen Kent and Ms Caroline Powell; courtesy of the NIBSC Centralized Facility for AIDS Reagents). Intracytoplasmic immunostaining was performed after incubating the cells for 1 h in blocking/permeabilizing solution (PBS, 2% goat serum, 0.1% saponin), with a mouse anti-MV-N mAb (MAB8906F; Chemicon International). In both cases the secondary antibody was a FITC-conjugated sheep anti-mouse IgG antibody (74641, BioRad). After 2 washing steps in PBS, cell nuclei were stained with DAPI.
Western blotting
CEMx174 cells were infected with the MV-SIVenv chimeric virus at an MOI of 0.1. Infected cells were collected 48 h later and lysed with complete EDTA-free protease inhibitor (Roche) in 120 mM NaCl solution. Protein lysates were separated (50 ng per well) by SDS-PAGE electrophoresis on 4-12% NUPAGE® Bis-Tris gels with MOPS running buffer (Invitrogen) before transfer to cellulose membranes with the XCell SureLock™ system (Invitrogen). To detect the SIVgp160 and MV-N proteins, the membranes were blotted with a mouse anti-SIVgp160/gp120 V2 monoclonal antibody (KK13; obtained from the Programme EVA Centre for AIDS Reagents, NIBSC, UK, supported by the EC FP6/7 Europrise Network of Excellence, AVIP and NGIN consortia and the Bill and Melinda Gates GHRC-CAVD Project and donated by Dr Karen Kent, NIBSC Centralized Facility for AIDS Reagents), or a mouse anti-MV N mAb (MAB8906F; Chemicon International). A sheep anti-mouse IgG-horseradish peroxidase (HRP) conjugate (NA931V; GE Healthcare) was used as secondary antibody. Peroxidase activity was visualized with an enhanced chemiluminescence detection kit (Pierce).
Electron microscopy
HeLa P4C5 cells were seeded on glass coverslips and infected at an MOI of 0.1 with the MV-SIVenv chimera. The cells were fixed 22 h later with 2% PFA in PBS for 5 min and with 4% PFA for 2 h at room temperature. Non-specific sites were saturated for 10 min with 1% bovine serum albumin, and the cells were probed for 40 min with the mouse anti-SIVMac251gp160/gp120 monoclonal antibody KK17 (NIH-AIDS Research and Reference Reagent Program) in PBS-1% BSA. After washing, the cells were incubated for 20 min with 10-nm colloidal gold particles coated with protein A (University Medical Center, Utrecht). The cells were then fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer overnight at 4°C, postfixed with 1% osmic acid, dehydrated in ethanol, and embedded in Epon. Ultrathin sections (70-80 nm) were cut with a diamond knife, stained with uranyl acetate and Reynolds lead citrate, and observed at 80 kV accelerating voltage in a JEOL JEM 1010 electron microscope equipped with an Eloïse Mega View III camera. Non-infected cells and HeLa P4C5 cells infected with MV-Schw were used as controls.
